Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2026-01-24 @ 3:20 AM
Study NCT ID:
NCT02447003
Status:
COMPLETED
Last Update Posted:
2020-12-16
First Post:
2015-05-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-11
Start Date Type:
ACTUAL
Primary Completion Date:
2019-02-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-01-31
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-14
First Submit QC Date:
None
Study First Post Date:
2015-05-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-11-18
Results First Submit QC Date:
None
Results First Post Date:
2020-12-16
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-11-18
Last Update Post Date:
2020-12-16
Last Update Post Date Type:
ACTUAL